Published: 28 June 2021
Author(s): Raimondo De Cristofaro, Maurizio Sanguinetti
Section: Letter to the Editor

We have read with great interest two recent contributions to the Clinical Insights section of the Journal concerning reports of thromboembolic complications associated with the administration of the COVID-19 vaccine by Astra Zeneca [1,2]. Since its initial outbreak in December 2019, Coronavirus disease 2019 (COVID-19) has become a rampant pandemic responsible for more than 140 million confirmed cases and more than 3 million deaths as of the end of April 2021. At such a pivotal time, rapid, worldwide vaccination against the SARS-CoV-2 virus to achieve herd immunity has become the most pressing issue for combat the global threat of the virus.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.